Although the Asia Pacific open surgery instrument market will be severely impacted by the COVID-19 pandemic in the short term, once conditions improve, the instrument market will return to moderate growth through 2029. China and India will be major centers of growth due to their improving health care infrastructure and promising economic and demographic landscapes. Additionally, the markets in South Korea and Australia will grow, primarily as a result of demand for innovative and premium-priced products, especially in the direct energy device segment. While the use of open surgery instruments continues to increase—driven by the uptake of innovative premium-priced products—declining open procedure volumes will continue to hinder overall market growth.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for open surgery instruments in the Asia Pacific region across a 10-year period.
The COVID-19 pandemic will have a negative impact on the open surgery device market.
To what extent will the COVID-19 pandemic impact the open surgery device market in Asia Pacific?
Which procedures are going to be affected the most during the pandemic?
How quickly are procedure volumes expected to rebound?
Surgeons and health care facilities are increasingly opting to use advanced direct energy devices for open surgical procedures.
What factors are driving the use of advanced energy devices for these surgeries?
Will ASPs decline or increase as a result of such a preference?
What strategies do competitors use to drive adoption in Indian and Chinese markets?
The closure device market will be limited by increasing commoditization of such products.
Which segments are growing and what factors are fueling revenue expansion?
How much of a role do domestic players have in the market?
What new technologies and devices have been introduced into the market?
- Open Surgery Instruments - Market Insights - Asia Pacific
Author(s): Vijjapu Kameswara Rao, MS Pharm
Vijjapu Kameswara Rao is a research associate on the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at DRG (Part of Clarivate), specializing in the gynecological device market. Kamesh holds a Bachelor's degree in Pharmaceutical Sciences from the Jawaharlal Nehru Technological University Kakinada and a Master's degree in Pharmaceutical Analysis from the National Institute of Pharmaceutical Education and Research, Mohali.